Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Box 100245, Gainesville, FL 32610, USA.
Bioorg Med Chem Lett. 2013 Oct 15;23(20):5646-9. doi: 10.1016/j.bmcl.2013.08.019. Epub 2013 Aug 13.
The high resolution crystal structure of 5-(2-thienylacetamido)-1,3,4-thiadiazole-2-sulfonamide complexed to human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoform hCA II is reported. The compound binds in a similar manner with acetazolamide when the sulfamoyl-thiadiazolyl-acetamido fragment of the two compounds is considered, but the thienyl tail was positioned in the subpocket 2, rarely observed by other investigated CA inhibitors. This positioning allows interaction with amino acid residues (such as Asn67, Ile91, Gln92 and Val121 which are variable in other isoforms of medicinal chemistry interest, such as hCA I, IX and XII. Indeed, the investigated sulfonamide was a medium potency hCA I and II inhibitor but was highly effective as a hCA IX and XII inhibitor. This different behavior with respect to acetazolamide (a promiscuous inhibitor of all these isoforms) has been explained by resolving the crystal structure, and may be used to design more isoform-selective compounds.
报告了 5-(2-噻吩乙酰氨基)-1,3,4-噻二唑-2-磺酰胺与人(h)碳酸酐酶(CA,EC 4.2.1.1)同工型 hCA II 的高分辨率晶体结构复合物。当考虑两种化合物的磺酰胺-噻二唑基-乙酰氨基片段时,该化合物以类似于乙酰唑胺的方式结合,但噻吩基尾部位于亚口袋 2 中,这在其他研究的 CA 抑制剂中很少观察到。这种定位允许与氨基酸残基相互作用(如 Asn67、Ile91、Gln92 和 Val121,它们在其他具有医学化学意义的同工型中是可变的,如 hCA I、IX 和 XII。事实上,研究的磺酰胺是一种中等效力的 hCA I 和 II 抑制剂,但对 hCA IX 和 XII 具有很高的抑制作用。与乙酰唑胺(所有这些同工型的广谱抑制剂)相比,这种不同的行为已经通过解析晶体结构得到了解释,并且可以用于设计更具同工型选择性的化合物。